Last reviewed · How we verify
HTL0039732 Capsules and atezolizumab infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HTL0039732 Capsules and atezolizumab infusion (HTL0039732 Capsules and atezolizumab infusion) — Cancer Research UK.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HTL0039732 Capsules and atezolizumab infusion TARGET | HTL0039732 Capsules and atezolizumab infusion | Cancer Research UK | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HTL0039732 Capsules and atezolizumab infusion CI watch — RSS
- HTL0039732 Capsules and atezolizumab infusion CI watch — Atom
- HTL0039732 Capsules and atezolizumab infusion CI watch — JSON
- HTL0039732 Capsules and atezolizumab infusion alone — RSS
Cite this brief
Drug Landscape (2026). HTL0039732 Capsules and atezolizumab infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/htl0039732-capsules-and-atezolizumab-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab